Olaptesed Pegol
- Generic Name
- Olaptesed Pegol
- Drug Type
- Small Molecule
- CAS Number
- 1390628-22-4
- Unique Ingredient Identifier
- MTM792B442
- Background
Olaptesed Pegol has been investigated for the treatment of Hematopoietic Stem Cell Transplantation.
Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- TME Pharma AG
- Target Recruit Count
- 60
- Registration Number
- NCT04901741
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
- Conditions
- Glioblastoma
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- TME Pharma AG
- Target Recruit Count
- 27
- Registration Number
- NCT04121455
- Locations
- 🇩🇪
Klinik und Poliklinik für Neurologie Schwerpunkt Klinische Neuroonkologie, Bonn, Germany
🇩🇪Klinik für Strahlentherapie und Radioonkologie, Mannheim, Germany
🇩🇪Klinik für Neurologie, Essen, Germany
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- TME Pharma AG
- Target Recruit Count
- 28
- Registration Number
- NCT01521533
- Locations
- 🇫🇷
Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France
🇦🇹Wilhelminenspital, Department of Medicine I, Center of Oncology and Hematology, Vienna, Austria
🇩🇪University Hospital Freiburg, Medizinische Universitätsklinik, Innere Medizin I, Haematologie und Onkologie, Freiburg, Germany
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- TME Pharma AG
- Target Recruit Count
- 28
- Registration Number
- NCT01486797
- Locations
- 🇦🇹
Medical University Innsbruck, Division of Hematology and Oncology, Innsbruck, Austria
🇧🇪Institute Jules Bordet, Department of Hematology, Brussels, Belgium
🇧🇪Cliniques universitaires Saint-Luc, Brussels, Belgium
NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- TME Pharma AG
- Target Recruit Count
- 12
- Registration Number
- NCT01194934
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
NOX-A12 First-in-human (FIH) Study
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- TME Pharma AG
- Target Recruit Count
- 48
- Registration Number
- NCT00976378
- Locations
- 🇩🇪
Scope Life Sciences GmbH, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.